Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. [PDF]
PLoS ONE, 2012 Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function.
Matthias Braun +14 more
doaj +1 more source
Pancreas and islet cell transplantation [PDF]
, 2002 Currently, for the patient with type 1 diabetes, a definitive treatment without resorting to the use of exogenous insulin can be achieved only with pancreas or islet cell transplantation.
A.N. Balamurugan +94 more
core +1 more source
BMEMat, EarlyView.Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen +7 more
wiley +1 more source
Perfil dos pacientes submetidos à angioplastia trasluminal coronariana com stents farmacológicos no Instituto de Cardiologia de Santa Catarina. [PDF]
, 2007 Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Aquino, Vivian Wuerges de
core
Automated processing of whole blood samples for the determination of immunosuppressants by liquid chromatography tandem-mass spectrometry [PDF]
, 2006 Background: Liquid chromatography tandem-mass spectrometry (LC-MS/MS) is an efficient technology for routine determination of immunosuppressants in whole blood; however, time-consuming manual sample preparation remains a significant limitation of this ...
Spöhrer, Ute, Vogeser, Michael
core +1 more source
Severe adverse events during sirolimus “off‐label” therapy for vascular anomalies
Pediatric Blood & Cancer, 2020 Clinical studies have shown low toxicity and a favorable safety profile for sirolimus in vascular anomalies. Here, we describe severe adverse events (SAEs) observed during “off‐label use” for vascular anomalies.
J. Rössler +14 more
semanticscholar +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi +6 more
wiley +1 more source
Drug Interaction between Sirolimus and Ranolazine in a Kidney Transplant Patient
Case Reports in Transplantation, 2014 Purpose. The case of a kidney transplant recipient who experienced a probable drug interaction between sirolimus and ranolazine is reported. Summary.
Joanna C. Masters +2 more
doaj +1 more source
Sirolimus-Induced Rash in a Kidney Transplant Patient
European Journal of Case Reports in Internal Medicine, 2022 Sirolimus is an inhibitor of the mammalian target of rapamycin, which is used in kidney transplant immunosuppression. The clinical spectrum of cutaneous adverse events associated with sirolimus use varies, with maculopapular rash being an uncommon side ...
Zachary Bruss +3 more
doaj +1 more source
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core